All thrombotic events (including myocardial infarction, ischaemic stroke, other arterial thromboembolism, and venous thromboembolism) · cardiac surgery for the treatment of non‐surgical bleeding
It is very uncertain whether PCC changes thrombotic events compared with FVIIa (very low certainty).
1 finding from 1 review
Mortality (30‐day) · cardiac surgery for the treatment of non‐surgical bleeding
It is very uncertain whether PCC changes mortality (30‐day) compared with FVIIa (very low certainty).
1 finding from 1 review
Bleeding (chest drain output) in mLs for the first 12 hours · cardiac surgery for the treatment of non‐surgical bleeding
1 finding from 1 review
Length of critical care stay (hours) · cardiac surgery for the treatment of non‐surgical bleeding
1 finding from 1 review
Incidence of renal impairment · cardiac surgery for the treatment of non‐surgical bleeding
It is very uncertain whether PCC changes incidence of renal impairment compared with FVIIa (very low certainty).
1 finding from 1 review
Adverse events · cardiac surgery for the treatment of non‐surgical bleeding
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Blood products transfused (RBC) % of patients · cardiac surgery for the treatment of non‐surgical bleeding
PCC showed no clear difference in blood products transfused (RBC) % of patients compared with standard treatment (low certainty).
1 finding from 1 review
All thrombotic events (including myocardial infarction, ischaemic stroke, other arterial thromboembolism, and venous thromboembolism) · cardiac surgery for the treatment of non‐surgical bleeding
PCC showed no clear difference in thrombotic events compared with standard treatment (moderate certainty).
1 finding from 1 review
Mortality (30‐day) · cardiac surgery for the treatment of non‐surgical bleeding
PCC showed no clear difference in mortality (30‐day) compared with standard treatment (moderate certainty).
1 finding from 1 review
Length of critical care stay (hours) · cardiac surgery for the treatment of non‐surgical bleeding
1 finding from 1 review
Incidence of renal impairment · cardiac surgery for the treatment of non‐surgical bleeding
PCC showed no clear difference in incidence of renal impairment compared with standard treatment (low certainty).
1 finding from 1 review
Bleeding (chest drain output) in mLs for the first 12 hours · cardiac surgery for the treatment of non‐surgical bleeding
1 finding from 1 review
Adverse events · cardiac surgery for the treatment of non‐surgical bleeding
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Blood products transfused (RBC) in units ‐ intraoperative · cardiac surgery for the treatment of non‐surgical bleeding
1 finding from 1 review
FEV1 % predicted: relative change from baseline · adults and children with CF
1 finding from 1 review
Time to next exacerbation · adults and children with CF
1 finding from 1 review
Participants hospitalised for respiratory exacerbation · adults and children with CF
Summary of findings ‐ AZLI showed no clear difference in participants hospitalised for respiratory exacerbation compared with placebo (moderate certainty).
1 finding from 1 review
Adverse events (AEs) (1 or more events) · adults and children with CF
Summary of findings ‐ AZLI showed no clear difference in any AEs compared with placebo (moderate certainty).
1 finding from 1 review
All‐cause mortality · adults and children with CF
Summary of findings ‐ AZLI showed no clear difference in mortality compared with placebo (moderate certainty).
1 finding from 1 review
Intervention not reported
LASB vs placebo · adults with CRPS
1 finding from 1 review